Update 2026: miREIA assay kits have been discontinued as of January 1, 2026.
The microRNA project now continues exclusively on the Two-Tailed RT-qPCR (TT-PCR) platform.
Professor Motovska from Kralovske Vinohrady University Hospital presented results from a substudy PRAGUE-19 with Biovendor's miREIA assays on ESC congress together with the World Congress of Cardiology 2O19 in Paris, France.
The results provide clear evidence that miR-223-3p and miR-126-3p to miR-223-3p ratios are strong independent predictors of short- and long-term thrombotic events and can be used for ischemic risk stratification after AMI.
